BRPI0822405A8 - METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, METHOD FOR INHIBITING CELL PROLIFERATION, COMPOUND, AND METHOD FOR MANUFACTURING A COMPOUND - Google Patents

METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, METHOD FOR INHIBITING CELL PROLIFERATION, COMPOUND, AND METHOD FOR MANUFACTURING A COMPOUND

Info

Publication number
BRPI0822405A8
BRPI0822405A8 BRPI0822405A BRPI0822405A BRPI0822405A8 BR PI0822405 A8 BRPI0822405 A8 BR PI0822405A8 BR PI0822405 A BRPI0822405 A BR PI0822405A BR PI0822405 A BRPI0822405 A BR PI0822405A BR PI0822405 A8 BRPI0822405 A8 BR PI0822405A8
Authority
BR
Brazil
Prior art keywords
compound
group
pharmaceutical composition
disease
treatment
Prior art date
Application number
BRPI0822405A
Other languages
Portuguese (pt)
Inventor
Yan John
Zheng Xiaoxia
D Bhat Vinayak
Original Assignee
Elixir Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Medical Corp filed Critical Elixir Medical Corp
Publication of BRPI0822405A2 publication Critical patent/BRPI0822405A2/en
Publication of BRPI0822405A8 publication Critical patent/BRPI0822405A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

MÉTODO PARA TRATAR UMA CONDIÇÃO OU DOENÇA OFTÁLMICA, COMPOSIÇÃO FARMACÊUTICA, DISPOSITIVO PARA O USO INTRACORPORAL, E, MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR. A presente invenção fornece uma composição farmacêutica que compreende um excipiente farmaceuticamente aceitável e um composto da fórmula (I) em que R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 e M7 são cada um independentemente um membro selecionado do grupo que consiste de H, alquila C1-6, OH e hidroxialquila C1-6; R4, R7 e R9 são cada um independentemente selecionados do grupo que consiste de alcóxi C1-6 e OH; R10 é um membro selecionado do grupo que consiste de H, -OH, -OP(O)Me2, -O-(CH2)n-OH e -O-(CH2)m,-O-(CH2)0-CH3, em que os subscritos n e m são cada um independentemente de 2 a 8 e o subscrito o é de 1 a 6; cada um de L1 e L4 é independentemente selecionado do grupo que consiste de em que cada M8 é independentemente um membro selecionado do grupo que consiste de alquila C1-6, OH e hidroxialquila C1-6; cada um de L2 e L3 é independentemente selecionado do grupo que consiste de; e sais, hidratos, isômeros, metabolitos, N-óxidos e pré-drogas do mesmo.METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, AND, METHOD FOR INHIBITING CELL PROLIFERATION. The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I) wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each one is independently a member selected from the group consisting of H, C1-6 alkyl, OH and hydroxyC1-6 alkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, -OH, -OP(O)Me2, -O-(CH2)n-OH and -O-(CH2)m,-O-(CH2)O-CH3, wherein the subscripts n and m are each independently from 2 to 8 and the subscript o is from 1 to 6; each of L1 and L4 is independently selected from the group consisting of wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 is independently selected from the group it consists of; and salts, hydrates, isomers, metabolites, N-oxides and pre-drugs thereof.

BRPI0822405A 2008-03-11 2008-03-11 METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, METHOD FOR INHIBITING CELL PROLIFERATION, COMPOUND, AND METHOD FOR MANUFACTURING A COMPOUND BRPI0822405A8 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/056501 WO2009114010A1 (en) 2008-03-11 2008-03-11 Macrocyclic lactone compounds and methods for their use

Publications (2)

Publication Number Publication Date
BRPI0822405A2 BRPI0822405A2 (en) 2018-05-15
BRPI0822405A8 true BRPI0822405A8 (en) 2018-06-05

Family

ID=41065507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822405A BRPI0822405A8 (en) 2008-03-11 2008-03-11 METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, METHOD FOR INHIBITING CELL PROLIFERATION, COMPOUND, AND METHOD FOR MANUFACTURING A COMPOUND

Country Status (6)

Country Link
EP (1) EP2254412A4 (en)
JP (1) JP2011525890A (en)
CN (1) CN102215682A (en)
BR (1) BRPI0822405A8 (en)
IL (1) IL208026A0 (en)
WO (1) WO2009114010A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
CN103387572B (en) * 2013-07-17 2015-09-30 成都雅途生物技术有限公司 Everolimus defects inspecting reference marker and preparation method thereof
CN107759616B (en) * 2016-08-23 2020-11-17 上海微创医疗器械（集团）有限公司 Compound and preparation method and application thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN113801104B (en) * 2020-06-15 2023-12-08 鲁南制药集团股份有限公司 Preparation method of hydrolysis impurity of ivermectin Mo Sida cyclic lactone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994012655A1 (en) * 1992-11-20 1994-06-09 Smithkline Beecham Corporation Process for producing rapamycin derivatives
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
WO2006108065A2 (en) * 2005-04-05 2006-10-12 Elixir Medical Corporation Degradable implantable medical devices
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
CN104906087A (en) * 2006-09-13 2015-09-16 万能医药公司 Macrocyclic lactone compounds and methods for their use

Also Published As

Publication number Publication date
BRPI0822405A2 (en) 2018-05-15
WO2009114010A1 (en) 2009-09-17
EP2254412A1 (en) 2010-12-01
EP2254412A4 (en) 2012-05-09
CN102215682A (en) 2011-10-12
IL208026A0 (en) 2010-12-30
JP2011525890A (en) 2011-09-29

Similar Documents

Publication Publication Date Title
BRPI0822405A8 (en) METHOD FOR TREATMENT OF AN OPHTHALMIC CONDITION OR DISEASE, PHARMACEUTICAL COMPOSITION, DEVICE FOR INTRABODY USE, METHOD FOR INHIBITING CELL PROLIFERATION, COMPOUND, AND METHOD FOR MANUFACTURING A COMPOUND
BR112018072570A2 (en) piperidines as girl inhibitors
BR112015022787A2 (en) compounds, pharmaceutical compositions, kit or packaged pharmaceutical article, and method of treating a carm1-mediated disorder
BR112018075663A2 (en) compounds and compositions for inhibiting shp2 activity
BR112019006712A2 (en) compound, pharmaceutical composition, composition for use in treating a disease, implantable element, and device.
NI201600166A (en) IMIDAZO [4, 5-C] QUINOLIN-2-ONA COMPOUNDS AND THEIR USE TO TREAT CANCER
BR112014018990A8 (en) BENZOTHIAZOLE-6-ILACETIC ACID DERIVATIVES AND THEIR USE FOR TREATMENT OF AN INFECTION
CL2014003181A1 (en) Compounds derived from n-substituted benzamides or n-substituted pyridinamides; pharmaceutical composition that includes them; treatment method; and its use for the treatment of selected diseases or disorders of pain, depression and cardiovascular, respiratory or psychiatric diseases or combinations thereof.
BR112016028642A2 (en) compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof.
BR112014019478A2 (en) a pharmaceutically acceptable salt or compound thereof, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, sodium channel inhibitor formulation, methods for treating and / or preventing pain and disease.
BR112016028876A2 (en) compound, pharmaceutical composition, method for treating a disease or condition in a human, kit, and use of a compound, a salt, isomer or a pharmaceutically acceptable mixture thereof.
BR112016028818A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and inhibiting excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, salt, isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, isomer, or a pharmaceutically acceptable mixture thereof.
BR112014013974A8 (en) benzyl sulfonamide derivatives as rorc modulators
DOP2012000310A (en) MORPHOLINOPIRIMIDINAS AND ITS USE IN THERAPY
BR122013028005B8 (en) hydroxylated and methoxylated pyrimidyl cyclopentane compounds, pharmaceutical composition, kit and oral dosage form comprising said compounds, use of said compositions, as well as process for preparing said compounds
BR112016028814A2 (en) pharmaceutical composition, methods of treating a disease or condition, inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof?
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
BR112016015365A8 (en) compound, pharmaceutical composition and use of a compound
BR112013028430A2 (en) compound, pharmaceutical composition, method for treating a spleen tyrosine kinase (syk) mediated disease or condition, and use of a therapeutically efficient amount of the compound
BR112015014458A8 (en) mannose derivatives, their intermediates, composition, use and preparation processes
BR112014011850A8 (en) AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
BR112015015653A8 (en) compound, method of preparing the compounds, compound for use, pharmaceutical composition and in vitro methods
BR112013001632A2 (en) compound, pharmaceutical composition, method of inhibiting a jak kinase activity in vitro, use of a compound, or pharmaceutical composition, and method of making a compound
BR112014000563A2 (en) compound, pharmaceutical composition, and compound use
BR112013016856A2 (en) compound, use of a compound, pharmaceutical composition and pharmaceutical

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/70 (2006.01), A61K 31/436 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.